The activities of some commonly used antituberculosis drugs were investigated within unstimulated peritoneal macrophages and in 7H-9 medium without Tween 80 using Mycobacterium microti OV254 as the target organism. In macrophage cultures, serial concentrations of isoniazid, rifampin, pyrazinamide, or streptomycin were added after a 2.5-h phagocytosis period. Viable counts were carried out at daily intervals for 5 or 6 days. The patterns of susceptibility to the four drugs were similar for M. microti and Mycobacterium tuberculosis. To ensure comparability with daily drug replacements in the macrophage experiments, the period of exposure to drugs in 7H-9 medium was kept to only 3 days. With in vitro culture at pH 6.4, drug penetration, measured as the ratio of MICs in macrophages to MICs in 7H-9 medium, was approximately 5 for isoniazid, 5 for rifampin, and 10 for streptomycin. With in vitro culture at pH 7.4, drug penetration was 100 for streptomycin, and at pH 5.6 it was 1 for pyrazinamide. Pyrazinamide was only bacteriostatic in macrophages but weakly bactericidal during the first day of exposure in vitro.
Mycobacterium microti resembles Mycobacteriium tutberculosis and has been used as an alternative to Mycobacterium bovis BCG for vaccinating children in Britain against tuberculosis (10) . It is a convenient organism for laboratory studies because of its low virulence in humans, and M. microti OV254 has therefore been used by several workers, particularly in this laboratory, for studying phenomena relevant to the pathogenesis of tuberculosis in cultures of macrophages (9, 16, 17, 28) . Recently, these studies have extended to the interaction between factors affecting immunity, including administration of lymphokines, and the activities of antituberculosis drugs (13) . To interpret the results of such studies, we needed to know the activities of antituberculosis drugs within macrophages. Intracellular drug activity has been studied previously using radiolabeled drugs or with M. tuberculosis or M. bovis as the target organism (1, 4-8, 15, 18, 19, 26 ; N. Rastogi, M. C. Potar, and H. L. David, Letter, Antimicrob. Agents Chemother. 32:287, 1988 ), but there are no similar reports using M. microti. We have therefore examined the activities of the commonly used antituberculosis drugs, isoniazid, rifampin, pyrazinamide, and streptomycin, by doing serial CFU counts of M. microti OV254 in mouse peritoneal macrophages (PM) at different drug concentrations. The second aim of the study was to measure the penetration of the drugs into the macrophages by comparing MICs obtained in the macrophage with in vitro MICs obtained in a similar manner by serial CFU counts on cultures of M. microti containing a range of drug concentrations. Since the drugs were replaced daily in the macrophage cultures, the period of exposure to drugs in the culture medium was kept to only 3 days, a period as brief as possible consistent with measuring antibacterial activity. The MICs obtained in the macrophages and in culture medium are therefore comparable and could be used to measure more accurately than has previously been possible the effective penetration of the drugs into macrophages. * Corresponding author.
MATERIALS AND METHODS
Media. All tissue culture media and supplements were obtained from GIBCO-Europe Ltd. (Uxbridge, United Kingdom) unless specified otherwise. Dubos broth was prepared double strength (DSDB) from Dubos broth base (Difco Laboratories, West Molesey, Surrey, United Kingdom). Basic maintenance medium contained 5.9 ml of medium 199, 4 ml of heat-inactivated horse serum, 0.4 ml of bovine embryo extract (Flow Laboratories, Woodcock Hill, Hertfordshire, United Kingdom), and 0.1 ml of liver fraction L (1 mg/ml; United States Biochemical Corp., Cleveland, Ohio). Bacteria The resulting monolayers of PM were cultured in basic maintenance medium.
(ii) Addition of M. microti and drug. A 6-day culture of M. microti in DSDB was washed twice by centrifugation at 1,000 x g for 15 min and suspended in Hanks balanced salt solution-HEPES (N-2-hydroxyethyipiperazine-N'-2-ethanesulfonic acid) buffer and then ultrasonicated for 12 s (Rinco Vitrasonics UK Ltd., London, United Kingdom). The infective inoculum was prepared to give a bacteria to PM ratio of 1:1. After a phagocytosis period of 2.5 h, monolayers were washed four times to remove unattached mycobacteria and overlaid with fresh medium plus drug, diluted from stock in basic maintenance medium, at various concentrations (day 0). The medium and drug over the monolayers were replaced daily for 5 or 6 days.
(iii) Viable counts. PM were removed by scraping them from the Linbro wells with a polytetrafluorethylene-tipped rod and aspirating the cell suspensions, which were briefly ultrasonicated to disrupt cell clumps. Serial 10-fold dilutions were made first in digitonin (0.8 mg/ml) to lyse cells and then in distilled water, and 0.05-ml volumes were pipetted onto one-third segments of Dubos oleic base agar medium plates (Difco). Plates were packed into polyethylene bags and incubated for 6 weeks at 37°C before CFU were counted. CFU counts were also set up on the well supernatants as a check on extracellular growth, which was always negligible.
In vitro titrations. After autoclaving, the pH of 7H-9 medium (Difco) without Tween 80 was adjusted with N/10 NaOH or HCl, and a 6-day culture of M. microti in DSDB was added (5 ml in 100 ml). After incubation for 3 days, the inoculated medium was dispensed into 30-ml screw-cap bottles and drugs were added. Over a 3-day period of incubation at 37°C, daily samples were ultrasonicated briefly, and viable counts were set up as above.
RESULTS
Each of the estimates of the MIC obtained in PM and in vitro was based on two or more experiments, except for the single experiment with rifampin in vitro. The MIC was taken as the lowest concentration that almost or completely inhibited growth and also yielded a curve distinctly lower than the curve for the drug-free control.
Isoniazid. The MICs of isoniazid were 0.05 pg/ml in PM and 0.01 Vig/ml in vitro at pH 6.4 (Fig. 1) Fig. 3 . The in vitro curves show slight bactericidal activity during the first day, which was also found in another of the three consistent experiments but not in the third experiment. The MIC was taken as 20 ,ug/ml, although there seemed to be slight activity at 5 and 10 p.g/ml. Neither of the endpoints in PM or in vitro is sharp. No appreciable regrowth occurred in PM or in vitro at the ends of the experiments when the pH of the in vitro experiment was still 5.6. Streptomycin. Titrations were done in the range of 30 to 0.05 pLg of streptomycin per ml. The MIC in PM was 5 Vsg/ml (Fig. 4) ; the curve for this concentration and for 10 pLg/ml showed bacteriostasis only, while 30 p.g/ml was bactericidal. The MIC in vitro (Fig. 5 ) at pH 6.4 was 0.5 pg/ml, which was bactericidal, whereas at pH 7.4 the MIC was 0.05 [.g/ml.
These titrations show fairly sharp endpoints. In vitro, concentrations of 1 to 20 pLg of streptomycin per ml were bactericidal at pH values of 5.8, 6.4, and 7.4, but lower concentrations were not tested at pH 5.8. with a target organism and grown in medium containing serial concentrations of drug, as we have done. However, in previous studies (5-8, 18, 19, 26) , the drug concentrations have not been sufficiently closely spaced to allow accurate estimations of the MICs, and of greater importance, a comparison has then been made between the intracellular MIC and an MIC obtained in vitro using a larger inoculum and a longer period of incubation, both of which may increase the MIC, and a medium containing Tween 80, which greatly decreases the MIC of most drugs. Even estimations of the MIC by the radiometric method in 7H-12 medium, which does not contain Tween 80 (Table 1) , are not directly comparable with the macrophage results, mainly because drugs in the macrophage cultures were replaced daily while radiometric results are read after an incubation period of 6 to 9 days, which is sufficiently long for deterioration of the drugs to occur, and also because the methods for determining the MICs are different. Our in vitro tests made it possible to make a more accurate comparison with the intracellular MICs because they were set up in medium without Tween 80, with a similar inoculum size and with an incubation period of only 3 days, longer than the 1-day intervals in the macrophage experiments but the minimum period necessary to demonstrate drug action. Nevertheless, there remains one potentially important difference between our intracellular and in vitro tests likely to affect the MICs. PM were cultured in medium containing 40% horse serum, reflecting the likely composition of inflammatory exudate, which might result in appreciable protein binding of the drug. However, the in vitro tests were in 7H-9 medium with only 0.5% bovine albumin, with little potential for protein binding. Thus, the ratio between the MIC in PM and the MIC in vitro should model not only the penetration and availability of the drug in PM but also the likely reduction of the MIC in PM by protein binding in their extracellular environment. We believe that our estimates of effective penetration are more accurate than previous measurements and are relevant to the choice of drug dosage in the treatment of tuberculosis.
The MIC of isoniazid against M. microti in PM was five times higher than the MIC in vitro (Table 1) . This finding, obtained with sharp endpoints and confirmed in duplicate experiments, is surprising since radiolabeled drug studies indicate similar intracellular and extracellular concentrations of isoniazid (1, 15) and its activity is not affected by pH (22) nor is it appreciably bound in plasma (3). Three possible explanations for this discrepancy might be advanced: intracellular activity may be reduced by intracellular binding or by antagonists or by metabolism within macrophages to an inactive compound, such as isonicotinic acid. Studies with radiolabeled rifampin suggest that it is concentrated two-to fivefold in alveolar macrophages (15) , although this might be due to concentration in lipid cell structures distant to the microenvironment of mycobacteria. Our finding that the MIC is five times lower in PM might therefore be the result of the high degree (85%) of binding of rifampin in plasma (2).
The similarity of the MICs of pyrazinamide in PM and in vitro confirm earlier studies (1, 7, 18) that it penetrates PM well. Accurate comparisons of the MICs in PM and in vitro are difficult, however, because of differences in the shapes of the CFU curves. Pyrazinamide was only bacteriostatic in PM, as found previously in human macrophages (7, 18) and in a macrophagelike cell line (Rastogi et al., Letter), while it was bactericidal during the first day of exposure in vitro. No regrowth (7) occurred during the 6 days of the exposure in PM, probably because the drug was replaced every day. The greater bactericidal activity in vitro than in PM supports the evidence from other observations (12) that the main sterilizing activity of pyrazinamide in human lesions is due to its action on extracellular organisms in areas of acute inflammation where the pH is particularly low (23) . This hypothesis explains the finding from clinical studies of pulmonary tuberculosis that pyrazinamide is an effective sterilizing drug during the early weeks of treatment, when areas of acute inflammation might be present, but loses this activity in the later months as inflammation dies down. It also suggests that pyrazinamide would not be useful for chemoprophylaxis of healed or dormant tuberculous lesions, since the bacilli in these would be in sites without acute inflammation. Our findings with streptomycin need little comment. They reflect the well-known decreased activity of streptomycin at lower pH values (20) and its much lower intracellular activity despite concentration in lysosomes (27 
